Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334265 | 0.89 | ADORA1 (0.34) | SMN1; SMN2ADORA2BADORA3ADORA2ATSHR | |
| SCHEMBL1333052 | 0.89 | KMT2A (0.41) | L3MBTL1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1334976 | 0.88 | L3MBTL1 (0.36) | L3MBTL1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1334329 | 0.85 | L3MBTL1 (0.38) | L3MBTL1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1332484 | 0.85 | ADORA2B (0.43) | SMN1; SMN2ADORA2BADORA3ADORA2ATSHR | |
| SCHEMBL1333453 | 0.83 | ADORA1 (0.44) | L3MBTL1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1333165 | 0.82 | ADORA2B (0.41) | KMT2ASMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL1333155 | 0.79 | KMT2A (0.44) | L3MBTL1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL1333502 | 0.79 | ADORA3 (0.38) | L3MBTL1SMN1; SMN2MAPTADORA2BADORA3 | |
| SCHEMBL1333212 | 0.79 | ADORA2B (0.44) | L3MBTL1SMN1; SMN2ADORA2BALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | claimed |
| US-7247639-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-08-25 | — | — | US | claimed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | WILSON CONSTANCE N (US) | 2011-11-17 | — | — | US | disclosed |
| US-7902360-B2 | e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | WILSON CONSTANCE N | 2011-03-08 | — | — | US | disclosed |
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7247639-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | ADORA1, ADORA3, ADORA2A | L3MBTL1 3587/4885KMT2A 2579/4885MEN1 711/4885 |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA3, ADORA2A | L3MBTL1 992/4885KMT2A 2755/4885MEN1 1077/4885 |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | L3MBTL1 2633/4885KMT2A 2329/4885MEN1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.